We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

269 hedge funds and large institutions have $3.73B invested in Ultragenyx Pharmaceutical in 2024 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 100 increasing their positions, 76 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

165% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 20

87% more call options, than puts

Call options by funds: $31.5M | Put options by funds: $16.9M

32% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 76

14% more funds holding

Funds holding: 236 → 269 (+33)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

4% less capital invested

Capital invested by funds: $3.87B → $3.73B (-$144M)

1.58% less ownership

Funds ownership: 98.64% → 97.06% (-1.6%)

Holders
269
Holders Change
+33
Holders Change %
+13.98%
% of All Funds
3.87%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
53
Increased
100
Reduced
76
Closed
20
Calls
$31.5M
Puts
$16.9M
Net Calls
+$14.6M
Net Calls Change
+$14.9M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$32M
2
ACA
Avoro Capital Advisors
New York
+$22.6M
3
BNP Paribas Asset Management
BNP Paribas Asset Management
France
+$20M
4
CS
Candriam SCA
Luxembourg
+$17.4M
5
EHI
Eagle Health Investments
Connecticut
+$14.1M

Top Sellers

1
CCM
Camber Capital Management
Massachusetts
-$43M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$41.3M
3
First Trust Advisors
First Trust Advisors
Illinois
-$37.5M
4
Morgan Stanley
Morgan Stanley
New York
-$32.6M
5
GPP
Great Point Partners
Connecticut
-$31M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$406M +$1.25M +26,575 +0.3%
RI
2
RTW Investments
New York
$331M +$9.44M +200,029 +3%
BlackRock
3
BlackRock
New York
$244M -$126K -2,662 -0.1%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$191M -$15M -317,054 -7%
Sands Capital Management
5
Sands Capital Management
Virginia
$180M -$12.2M -258,561 -6%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$167M +$5.67M +120,175 +3%
State Street
7
State Street
Massachusetts
$133M -$18.9M -401,252 -12%
ClearBridge Investments
8
ClearBridge Investments
New York
$112M +$819K +17,362 +0.7%
Alkeon Capital Management
9
Alkeon Capital Management
New York
$105M – – –
Federated Hermes
10
Federated Hermes
Pennsylvania
$90.5M -$24M -507,820 -21%
RSCM
11
Rock Springs Capital Management
Maryland
$82.9M +$986K +20,900 +1%
SCM
12
Suvretta Capital Management
New York
$78.3M -$21.2M -449,495 -21%
AllianceBernstein
13
AllianceBernstein
Tennessee
$69.2M -$4.53M -96,132 -6%
BBA
14
Baker Bros. Advisors
New York
$68.5M – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
$62.6M +$2.65M +56,204 +4%
Deutsche Bank
16
Deutsche Bank
Germany
$56.4M +$1.62M +34,359 +3%
Pictet Asset Management
17
Pictet Asset Management
Switzerland
$48.5M +$624K +13,238 +1%
Marshall Wace
18
Marshall Wace
United Kingdom
$45.2M -$24.6M -520,496 -35%
APM
19
Avidity Partners Management
Texas
$43.6M +$4.2M +89,000 +11%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$42.6M -$4.68M -99,174 -10%
ACA
21
Avoro Capital Advisors
New York
$38.8M +$22.6M +480,000 +137%
Norges Bank
22
Norges Bank
Norway
$37.3M +$1.32M +27,998 +4%
FLAM
23
First Light Asset Management
Minnesota
$36.9M +$2.16M +45,781 +6%
Fidelity Investments
24
Fidelity Investments
Massachusetts
$36.5M -$9.95M -210,919 -21%
Millennium Management
25
Millennium Management
New York
$33.1M +$32M +679,353 +2,379%
1
2 3 4 5

RARE Hedge Fund Activity: Q1 2024 in Review

269 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2024, worth a combined $3.73B — down 3.7% from $3.87B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new RARE positions and 20 closed out — a net gain of 33 holders — while 100 added to existing stakes and 76 trimmed.

The largest buyer was Millennium Management, adding an estimated $32M. The largest seller was Camber Capital Management, exiting entirely with an estimated $43M sold.

  • 269 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2024, up from 236 in Q4 2023.
  • Funds reported $3.73B of Ultragenyx Pharmaceutical stock for Q1 2024, down 3.7% quarter-over-quarter.
  • 53 funds opened new Ultragenyx Pharmaceutical positions in Q1 2024 and 20 closed out, a net change of +33 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q1 2024 was Millennium Management, an estimated $32M added.
  • The largest Ultragenyx Pharmaceutical seller in Q1 2024 was Camber Capital Management, an estimated $43M sold.

Based on aggregated 13F filings for Q1 2024.